0000899243-16-015241.txt : 20160303 0000899243-16-015241.hdr.sgml : 20160303 20160303214145 ACCESSION NUMBER: 0000899243-16-015241 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20160222 FILED AS OF DATE: 20160303 DATE AS OF CHANGE: 20160303 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Unilife Corp CENTRAL INDEX KEY: 0001476170 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 271049354 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 BUSINESS ADDRESS: STREET 1: 250 CROSS FARM LANE CITY: YORK STATE: PA ZIP: 17406 BUSINESS PHONE: (717) 384-3400 MAIL ADDRESS: STREET 1: 250 CROSS FARM LANE CITY: YORK STATE: PA ZIP: 17406 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: AMGEN INC CENTRAL INDEX KEY: 0000318154 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-34540 FILM NUMBER: 161483461 BUSINESS ADDRESS: STREET 1: ONE AMGEN CENTER DRIVE CITY: THOUSAND OAKS STATE: CA ZIP: 91320 BUSINESS PHONE: (805)447-1000 MAIL ADDRESS: STREET 1: ONE AMGEN CENTER DRIVE CITY: THOUSAND OAKS STATE: CA ZIP: 91320 FORMER NAME: FORMER CONFORMED NAME: AMGEN DATE OF NAME CHANGE: 19870305 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2016-02-22 0 0001476170 Unilife Corp UNIS 0000318154 AMGEN INC ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320 0 0 1 0 6% Senior Secured Convertible Note due 2023 2016-02-22 2023-02-22 Common Stock 36108393 D Includes shares issuable upon the conversion of interest accruable under the 6% Senior Secured Convertible Note due 2023 through maturity and payable through the addition of the amount of such interest to the then outstanding principal amount. The 6% Senior Secured Convertible Note due 2023 is convertible into shares of the Issuer's Common Stock at any time prior to February 22, 2023, at a price per share that is 90% of the volume weighted average price of such shares during the twenty (20) trading days preceding the applicable conversion date, subject to a floor price of $1.25 per share (the "Conversion Rate Floor Price"). The Conversion Rate Floor Price is subject to customary adjustments for certain capital events. Amgen Inc., by /s/ Andrea A. Robinson, Assistant Secretary and Associate General Counsel 2016-03-03